(资料图片仅供参考)

参考文献[1] Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial [published online ahead of print, 2023 Jun 26]. N Engl J Med. 2023;10.1056/NEJMoa2301972. doi:10.1056/NEJMoa2301972[2] Tsapas A，Karagiannis T，Kakotrichi P，et al.Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis[J]. Diabetes， obesity & metabolism. 2021 May 28.[3] Domenica M. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. JAMA，January 11, 2022.[4] Jastreboff, A., Arrone, J., Ahmad, N. et. al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022; 387:205-216 DOI: 10.1056/NEJMoa2206038[5] [6] 杨华等,中国肥胖代谢外科研究协作组.中国肥胖代谢外科数据库:2020年度报告[J].中华肥胖与代谢病电子杂志,2021,7(1):1-7[7] Arterburn D, Wellman R, Emiliano A, et al. Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss: A PCORnet Cohort Study. Ann Intern Med. 2018;169(11):741-750. doi:10.7326/M17-2786[8] /investors/financial-results.html[9] /news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development[10] FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.[11] /content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=165597[12] Domenica M. Rubino et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. JAMA，January 11, 2022.